Drug and Solute Transporters in Mediating Resistance to Novel Therapeutics in Multiple Myeloma

Rachel L Mynott, Craig T Wallington-Beddoe

Research output: Contribution to journalArticlepeer-review

Abstract

Multiple myeloma remains an incurable malignancy of plasma cells. Novel therapies, notably proteasome inhibitors and immunomodulatory drugs, have improved the survival of multiple myeloma patients; however, patients either present with, or develop resistance to, these therapies. Resistance to traditional chemotherapeutic agents can be caused by cellular drug efflux via adenosine triphosphate (ATP)-binding cassette (ABC) transporters, but it is still not clear whether these transporters mediate resistance to proteasome inhibitors and immunomodulatory drugs in multiple myeloma. Solute carrier (SLC) transporters also play a role in cancer drug resistance due to changes in cell homeostasis caused by their abnormal expression and changes in the solutes they transport. In this review, we evaluate resistance to novel therapies used to treat multiple myeloma, as mediated by drug and solute transporters.

Original languageEnglish
Number of pages16
JournalACS Pharmacology and Translational Science
Early online date15 Apr 2021
DOIs
Publication statusE-pub ahead of print - 15 Apr 2021

Keywords

  • Multiple myeloma
  • Drug resistance
  • ABC transporters
  • SLC transporters
  • multiple myeloma
  • drug resistance

Fingerprint Dive into the research topics of 'Drug and Solute Transporters in Mediating Resistance to Novel Therapeutics in Multiple Myeloma'. Together they form a unique fingerprint.

Cite this